Lumos Pharma (NASDAQ:LUMO) Chairman and CEO Rick Hawkins spoke to Proactive about the Austin, Texas-based group's aims to advance small molecule LUM-201 in Phase 2 studies to treat growth hormone deficiency in children.
Hawkins says interim analyses data for the company's OraGrowtH210 and PK/PD OraGrowtH212 clinical trials should be expected by end of 2022.